发明授权
- 专利标题： Positive allosteric modulators of MGLUR2
- 专利标题（中）： MGLUR2的正变构调节剂
-
申请号： US13814870申请日： 2011-08-05
-
公开(公告)号： US08993779B2公开(公告)日： 2015-03-31
- 发明人: Vadim Y. Dudkin , Mark E. Fraley , Kenneth L. Arrington , Mark E. Layton , Alexander J. Reif , Kevin J. Rodzinak , Joseph E. Pero
- 申请人： Vadim Y. Dudkin , Mark E. Fraley , Kenneth L. Arrington , Mark E. Layton , Alexander J. Reif , Kevin J. Rodzinak , Joseph E. Pero
- 申请人地址： US NJ Rahway
- 专利权人： Merck Sharp & Dohme Corp.
- 当前专利权人： Merck Sharp & Dohme Corp.
- 当前专利权人地址： US NJ Rahway
- 代理商 Keith D. MacMillan; John C. Todaro
- 国际申请： PCT/US2011/046677 WO 20110805
- 国际公布： WO2012/021382 WO 20120216
- 主分类号： C07D235/26
- IPC分类号： C07D235/26 ; C07D417/14 ; C07D403/04 ; C07D403/14 ; C07D401/04 ; C07D401/14 ; C07D401/06 ; C07D401/10 ; C07D401/12 ; C07D403/10 ; C07D405/06 ; C07D453/02 ; C07D513/14 ; C07D405/10 ; C07D409/10 ; C07D413/10 ; C07D471/04
摘要：
The present invention is directed to benzimidazolone derivatives which are positive allosteric modulators of the mGluR2 receptor, useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 receptor is involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved, such as schizophrenia.
公开/授权文献
- US20130143880A1 POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 公开/授权日：2013-06-06
信息查询
